The conversation is about using RU58841 for hair loss after finasteride didn't work, with the user considering trying RU before minoxidil. Another user suggests trying oral dutasteride and oral minoxidil first.
Transitioning from finasteride to dutasteride for hair loss, with suggestions to either slowly transition or frontload dutasteride. The user is also using minoxidil, nizoral, needling, and LLLT.
The conversation is about hair loss treatments, specifically mentioning finasteride, minoxidil, and the possibility of a hair transplant in Turkey. Users share humorous reactions and personal experiences with these treatments.
Dutasteride mesotherapy, combined with peptides and exosomes, is being considered for hair loss treatment. One user suggests that oral finasteride or dutasteride mesotherapy may not be necessary if already taking oral dutasteride.
Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.
The conversation is about adding Swisse Hair Nutrition for Men, which contains saw palmetto and various vitamins, to a Minoxidil and finasteride regimen to potentially enhance hair growth. The user is seeking feedback on the effectiveness of stacking these supplements with their current treatment.
A user shared their journey from balding to using a hair system, expressing satisfaction with the results despite the costs. They mentioned trying finasteride but stopped due to side effects, and now enjoy increased attention from women with the hair system.
A 34-year-old underwent a hair transplant with 5,250 grafts, stem cell therapy, and PRP at Dr. Hakan Clinic in Istanbul, without using Minoxidil or Finasteride. Despite initial concerns about the hairline design, the user is optimistic about the results and plans to update progress over time.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.
The user has been using 5% minoxidil, finasteride, and dutasteride, along with microneedling and ketoconazole, to treat hair loss, showing significant progress over a year. Side effects mentioned include brain fog, watery semen, and facial dryness.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
Koshine is considered less effective than finasteride, dutasteride, and RU58841 for hair loss treatment. One user reported positive results with Koshine, but others found it ineffective.
The user experienced worsening hair loss despite using dutasteride tablets and is considering switching to dutasteride gel capsules due to concerns about tablet bioavailability. Another user mentioned that countries like Japan, Korea, and India use the tablet form, suggesting the form may not be the issue.
The user experienced better hair thickening results with a combination pill of oral minoxidil (3mg) and finasteride (1mg) compared to previous treatments with topical minoxidil and finasteride alone. They reported no significant side effects and expressed regret for not starting this treatment earlier.
A user's successful hair regrowth after 7 months of using 5% minoxidil, 1mg finasteride, and adding micro needling 4 months ago. The user also took biotin, fish oil, and collagen supplements, and reduced finasteride intake to once every 3 days due to minor libido decay.
The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
Hair loss treatments like Dutasteride, RU58841, Finasteride, and Minoxidil are discussed, with skepticism about their effectiveness without photographic evidence. The conversation humorously critiques the reliance on anecdotal evidence for these treatments.
Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
A user started taking 0.5 mg of finasteride daily and noticed watery semen, questioning if it's normal or if they should adjust the dosage. Another user suggested it might indicate reduced fertility and may not improve.
Whey protein may slightly increase hair loss in men with androgenetic alopecia (AGA) due to elevated IGF-1 and testosterone levels, but the effect is minimal compared to treatments like finasteride and dutasteride. Many users argue that whey protein's impact on hair loss is negligible and that maintaining a healthy lifestyle is more important.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.